Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Idefirix Market Size Forecast: How Large Could The Market Become By 2030?
Growth in the historic period was driven by a shortage of organs available for kidney transplantation, a high prevalence of donor-specific antibodies, the shortcomings of conventional desensitization approaches, early clinical achievements with imlifidase, and an increase in the number of transplant centers.
The forecast period’s expansion is driven by a greater need for kidney transplants, longer transplant waiting lists, wider use of precision immunology, favorable regulatory frameworks, and more specialized transplant clinics emerging. Key developments shaping this period involve the increased application of desensitization treatments in transplantation, heightened attention on highly sensitized individuals, growth in enzyme-based immunomodulation, higher numbers of kidney transplants performed, and enhanced availability of sophisticated transplant care.
Download A Free Sample Report For Comprehensive Market Insights:
Idefirix Market Expansion Supported By Key Demand Factors
The growing frequency and occurrence of kidney disorders is anticipated to drive expansion in the idefirix market moving forward. Kidney diseases involve damage to the kidneys’ structure or function, which impairs their capacity to filter waste and preserve fluid balance within the body. This rise in kidney disease prevalence and incidence is linked to factors like an aging population, increased rates of diabetes and hypertension, lifestyle decisions, and hereditary factors. Idefirix, an innovative immunoglobulin G (IgG)-degrading enzyme therapy, assists kidney disease patients by facilitating life-saving transplants for highly sensitized individuals through effective reduction of donor-specific antibodies that would typically lead to transplant rejection. For example, a June 2023 report from kidney research, a UK-based research organization, indicated that acute kidney injury cases are predicted to climb from roughly 615,000 in 2022 to 637,000 by 2033. Hence, the rising prevalence and incidence of kidney diseases is fueling growth in the idefirix market.
Idefirix Market Segmentation And Category Breakdown
The idefirix market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Application: Kidney Transplantation, Desensitization Protocols
3) By End-User: Hospitals, Specialized Clinics, Home Healthcare
4) By Distribution Channel: Direct Sales, Pharmacies
Idefirix Market Growth Trends Influencing Competitive Dynamics
The main focus within the idefirix market revolves around creating advanced solutions, like desensitization therapy, aimed at making highly sensitized kidney transplant candidates less reactive. Such therapy is a medical approach designed to eliminate or lower detrimental antibodies, making it possible for patients to accept organs from incompatible donors. A notable development occurred in July 2023 when Hansa Biopharma, a biopharmaceutical firm based in Sweden, obtained approval from the Australian Therapeutic Goods Administration (TGA), an Australian regulatory body, for Idefirix (imlifidase) as a desensitization option for highly sensitized kidney transplant patients. This authorization allows these individuals to undergo kidney transplantation using organs from both living and deceased sources. The mechanism of this therapy involves minimizing or removing harmful anti-donor antibodies that typically impede transplantation. Drawing on favorable outcomes from Hansa Biopharma’s phase 2 trials, this endorsement represents a major advancement in broadening kidney transplant possibilities for highly sensitized patients in Australia.
Idefirix Market Competitive Analysis Of Major Industry Participants
Major companies operating in the idefirix market are Hansa Biopharma AB
Access The Complete Idefirix Market Report:
Idefirix Market Regional Analysis And Leading Geography
Europe was the largest region in the idefirix market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the idefirix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model